Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system
Tóm tắt
High activation of the angiotensin-converting enzyme (ACE)/(angiotensin-II type 1 receptor) AT1r axis is closely linked to pro-inflammatory effects and liver damage. The aim of this study was to evaluate the effects of the short-term administration of GW501516 on pro-inflammatory markers in white adipose tissue (WAT) and hepatic stellate cells (HSCs), lipogenesis and insulin resistance in the liver upon high-fructose diet (HFru)-induced ACE/AT1r axis activation. Three-month-old male C57Bl/6 mice were fed a standard chow diet or a HFru for 8 weeks. Then, the animals were separated randomly into four groups and treated with GW501516 for 3 weeks. Morphological variables, systolic blood pressure, and plasma determinations were analyzed. In the WAT, the ACE/AT1r axis and pro-inflammatory cytokines were assessed, and in the liver, the ACE/AT1r axis, HSCs, fatty acid oxidation, insulin resistance, and AMPK activation were evaluated. The HFru group displayed a high activation of the ACE/AT1r axis in both the WAT and liver; consequently, we detected inflammation and liver damage. Although GW501516 abolished the increased activation of the ACE/AT1r axis in the WAT, no differences were found in the liver. GW501516 blunted the inflammatory state in the WAT and reduced HSC activation in the liver. In addition, GW501516 alleviates damage in the liver by increasing the expression of the genes that regulate beta-oxidation and decreasing the expression of the genes and proteins that are involved in lipogenesis and gluconeogenesis. We conclude that GW501516 may serve as a therapeutic option for the treatment of a highly activated ACE/AT1r axis in WAT and liver.
Tài liệu tham khảo
R. Weiss, F.R. Kaufman, Metabolic complications of childhood obesity: identifying and mitigating the risk. Diabetes Care 31(Suppl 2), S310–S316 (2008)
N. Anderson, J. Borlak, Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60, 311–357 (2008)
M. Laville, J.A. Nazare, Diabetes, insulin resistance and sugars. Obes. Rev. 10(Suppl 1), 24–33 (2009)
C. Couchepin, K.A. Le, M. Bortolotti, J.A. da Encarnacao, J.B. Oboni, C. Tran et al., Markedly blunted metabolic effects of fructose in healthy young female subjects compared with male subjects. Diabetes Care 31, 1254–1256 (2008)
D.I. Jalal, G. Smits, R.J. Johnson, M. Chonchol, Increased fructose associates with elevated blood pressure. J. Am. Soc. Nephrol. 21, 1543–1549 (2010)
L. Tappy, K.A. Le, Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 90, 23–46 (2010)
S.H. Santos, L.R. Fernandes, C.S. Pereira, A.L. Guimaraes, A.M. de Paula, M.J. Campagnole-Santos et al., Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul. Pept. 178, 64–70 (2012)
T. Fukui, T. Hirano, Y. Shiraishi, M. Nagashima, M. Adachi, Chronic insulin infusion normalizes blood pressure and the gene expressions of angiotensin II type 1 receptor in fructose-fed rats. Hypertens. Res. 31, 127–133 (2008)
S.H. Santos, L.R. Fernandes, E.G. Mario, A.V. Ferreira, L.C. Porto, J.I. Alvarez-Leite et al., Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57, 340–347 (2008)
M. Granzow, R. Schierwagen, S. Klein, B. Kowallick, S. Huss, M. Linhart et al., Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60, 334–348 (2014)
K. Uyeda, J.J. Repa, Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4, 107–110 (2006)
N. Roglans, L. Vila, M. Farre, M. Alegret, R.M. Sanchez, M. Vazquez-Carrera et al., Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 45, 778–788 (2007)
L. Serrano-Marco, E. Barroso, I. El Kochairi, X. Palomer, L. Michalik, W. Wahli et al., The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 55, 743–751 (2012)
L. Serrano-Marco, R. Rodriguez-Calvo, I. El Kochairi, X. Palomer, L. Michalik, W. Wahli et al., Activation of peroxisome proliferator-activated receptor-beta/-delta (PPAR-beta/-delta) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 60, 1990–1999 (2011)
T. Coll, E. Barroso, D. Alvarez-Guardia, L. Serrano, L. Salvado, M. Merlos et al., The role of peroxisome proliferator-activated receptor beta/delta on the inflammatory basis of metabolic disease. PPAR Res. (2010). doi:10.1155/2010/368467
M.J. Zarzuelo, R. Jimenez, P. Galindo, M. Sanchez, A. Nieto, M. Romero et al., Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension 58, 733–743 (2011)
D.K. Kramer, L. Al-Khalili, B. Guigas, Y. Leng, P.M. Garcia-Roves, A. Krook, Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem. 282, 19313–19320 (2007)
D.C. Magliano, T.C. Bargut, S.N. de Carvalho, M.B. Aguila, C.A. Mandarim-de-Lacerda, V. Souza-Mello, Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice. PLoS One 8, 64258 (2013)
M. Catta-Preta, L.S. Mendonca, J. Fraulob-Aquino, M.B. Aguila, C.A. Mandarim-de-Lacerda, A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch. 459, 477–485 (2011)
M.B. Aguila, A.R. Pinheiro, L.B. Parente, C.A. Mandarim-de-Lacerda, Dietary effect of different high-fat diet on rat liver stereology. Liver Int. 23, 363–370 (2003)
S. Barbosa-da-Silva, N.C. da Silva, M.B. Aguila, C.A. Mandarim-de-Lacerda, Liver damage is not reversed during the lean period in diet-induced weight cycling in mice. Hepatol. Res. 44, 450–459 (2014)
A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S.C. Bischoff, I. Bergheim, Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50, 1094–1104 (2009)
A. Schultz, D. Neil, M.B. Aguila, C.A. Mandarim-de-Lacerda, Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int. J. Mol. Sci. 14, 21873–21886 (2013)
N. Sharma, L. Li, C.M. Ecelbarger, Sex differences in renal and metabolic responses to a high-fructose diet in mice. Am. J. Physiol. Renal Physiol. 308, F400–F410 (2015)
L.A. Bojic, D.E. Telford, M.D. Fullerton, R.J. Ford, B.G. Sutherland, J.Y. Edwards et al., PPARdelta activation attenuates hepatic steatosis in Ldlr−/− mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J. Lipid Res. 55, 1254–1266 (2014)
M.A. Prieto, A. Bettaieb, C.R. Lanzi, V.C. Soto, D.J. Perdicaro, C.R. Galmarini et al., Catechin and quercetin attenuate adipose inflammation in fructose-fed rats and in 3T3-L1 adipocytes. Mol. Nutr. Food Res. (2015). doi:10.1002/mnfr.201400631
N. Mamikutty, Z.C. Thent, S.R. Sapri, N.N. Sahruddin, M.R. MohdYusof, F. Haji Suhaimi, The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. BioMed Res. Int. 14, 263897 (2014)
W.X. Carroll, N.S. Kalupahana, S.L. Booker, N. Siriwardhana, M. Lemieux, A.M. Saxton et al., Angiotensinogen gene silencing reduces markers of lipid accumulation and inflammation in cultured adipocytes. Front. Endocrinol. 4, 10 (2013). doi:10.3389/fendo.2013.00010
E.S. Alves, A.A. Haidar, C.D. Quadros, D.S. Carvalho, D. Morgan, M.S. Rocha et al., Angiotensin II-induced JNK activation is mediated by NAD(P)H oxidase in isolated rat pancreatic islets. Regul. Pept. 175, 1–6 (2012)
K. Nomura, T. Yamanouchi, The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 23, 203–208 (2012)
Y. Nagai, Y. Nishio, T. Nakamura, H. Maegawa, R. Kikkawa, A. Kashiwagi, Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Am. J. Physiol. Endocrinol. Metab. 282, E1180–E1190 (2002)
M.A. Lanaspa, L.G. Sanchez-Lozada, C. Cicerchi, N. Li, C.A. Roncal-Jimenez, T. Ishimoto et al., Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One 7, e47948 (2012)
M.F. Abdelmalek, A. Suzuki, C. Guy, A. Unalp-Arida, R. Colvin, R.J. Johnson et al., Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010)
E. Barroso, A.M. Astudillo, J. Balsinde, M. Vazquez-Carrera, PPARbeta/delta Activation prevents hypertriglyceridemia caused by a high fat diet. Involvement of AMPK and PGC-1alpha-Lipin1-PPARalpha pathway. Clin. Investig. Arterioscler. 25, 63–73 (2013). doi:10.1016/j.arteri.2013.01.001
R.H. Houtkooper, E. Pirinen, J. Auwerx, Sirtuins as regulators of metabolism and health span. Nat. Rev. Mol. Cell Biol. 13, 225–238 (2012)
C. Canto, J. Auwerx, PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20, 98–105 (2009)
B. Viollet, L. Lantier, J. Devin-Leclerc, S. Hebrard, C. Amouyal, R. Mounier et al., Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci. 14, 3380–3400 (2009)
Y.G. Suh, W.I. Jeong, Hepatic stellate cells and innate immunity in alcoholic liver disease. World J. Gastroenterol. 17, 2543–2551 (2011)
M. Adachi, D.A. Brenner, High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47, 677–685 (2008)